WO2023031210 - STEREOCHEMICALLY PURE LIPIDS FOR NUCLEIC ACID DELIVERY
National phase entry:
Publication Number
WO/2023/031210
Publication Date
09.03.2023
International Application No.
PCT/EP2022/074100
International Filing Date
30.08.2022
Title **
[English]
STEREOCHEMICALLY PURE LIPIDS FOR NUCLEIC ACID DELIVERY
[French]
LIPIDES STÉRÉOCHIMIQUEMENT PURS POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES
Applicants **
STUDIENGESELLSCHAFT KOHLE gGMBH
Kaiser-Wilhelm-Platz 1
45470 Mülheim, DE
Inventors
LIST, Benjamin
Leonard-Stinnes-Strasse 43
-
45470 Mülheim an der Ruhr, DE
DE, Chandra Kanta
Dohne 53
45468 Mülheim an der Ruhr, DE
ZHU, Chendan
Kluse 43
45470 Mülheim an der Ruhr, DE
DEHN, Stefanie
Kleine Hammerstr. 50
45326 Essen, DE
HINRICHS, Heike
Obere Saarlandstr. 7
45470 Mülheim an der Ruhr, DE
Priority Data
21194182.8
31.08.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1018 | |
| EPO | Filing, Examination | 4562 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 3310 |
Total: 10052 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present application generally relates to stereochemically pure lipids that can be used, also in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles with oligonucleotides, to facilitate the intracellular delivery of therapeutic nucleic acids such as oligonucleotides, messenger RNA both in vitro and in vivo.[French]
La présente invention concerne d'une manière générale des lipides stéréochimiquement purs qui peuvent être utilisés, également en combinaison avec d'autres composants lipidiques, tels que des lipides neutres, du cholestérol et des lipides conjugués polymères, pour former des nanoparticules lipidiques avec des oligonucléotides, pour permettre l'administration intracellulaire d'acides nucléiques thérapeutiques tels que des oligonucléotides, de l'ARN messager à la fois in vitro et in vivo.